Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20482096 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL20440763 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL5177411 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL6674308 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL9872556 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL20439223 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL20482420 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL20482130 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| Hydrochloric Acid SCHEMBL20482410 | 0.98 | SLC6A3 (0.54) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| Hydrochloric Acid SCHEMBL3552029 | 0.98 | SLC6A3 (0.54) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-02 | — | — | US | disclosed |
| US-20230295619-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| WO-2023091644-A2 | HSD17B13-RELATED DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-25 | — | — | WO | disclosed |
| US-20230145795-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-11 | — | — | US | disclosed |
| US-20230145795-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-11 | — | — | US | disclosed |
| US-20150166999-A1 | CHIRAL NUCLEIC ACID ADJUVANT | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20150166999-A1 | CHIRAL NUCLEIC ACID ADJUVANT | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-2620428-A1 | ASYMMETRIC AUXILIARY GROUP | Chiralgen, Ltd. (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-20130178612-A1 | CHIRAL AUXILIARIES | CHIRALGEN, LTD. (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20130178612-A1 | CHIRAL AUXILIARIES | CHIRALGEN, LTD. (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20120316224-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | ONTORII, INC (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316224-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | ONTORII, INC (US) | 2012-12-13 | — | — | US | disclosed |
| US-20110294124-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | WAVE LIFE SCIENCES LTD. (SG) | 2011-12-01 | — | — | US | disclosed |
| US-20110294124-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | WAVE LIFE SCIENCES LTD. (SG) | 2011-12-01 | — | — | US | disclosed |
| WO-2010064146-A2 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | CHIRALGEN, LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178612-A1 | CHIRAL AUXILIARIES | POLL, PCNA, POLM | SLC6A3 3104/4885SLC6A2 3152/4885SLC6A4 2221/4885 |
| US-20120316224-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | PNP, RNGTT, TYMP | SLC6A3 829/4885SLC6A2 771/4885SLC6A4 639/4885 |
| US-20150166999-A1 | CHIRAL NUCLEIC ACID ADJUVANT | IFNAR1, IFNG, IRF3 | SLC6A3 3284/4885SLC6A2 3278/4885SLC6A4 2120/4885 |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | SLC6A3 3086/4885SLC6A2 2493/4885SLC6A4 1561/4885 |
| US-20230145795-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | ADAR, TRDMT1, RNMT | SLC6A3 1253/4885SLC6A2 2421/4885SLC6A4 2925/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | SLC6A3 3354/4885SLC6A2 3205/4885SLC6A4 1880/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | SLC6A3 2720/4885SLC6A2 2690/4885SLC6A4 1809/4885 |
| US-20110294124-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | PNP, ADAR, NUDT1 | SLC6A3 1682/4885SLC6A2 1809/4885SLC6A4 1910/4885 |
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | SLC6A3 3986/4885SLC6A2 4256/4885SLC6A4 2946/4885 |
| US-20230295619-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | MAPT, TRDMT1, FBL | SLC6A3 794/4885SLC6A2 767/4885SLC6A4 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.